Research Article
CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome
Table 2
Concentration and functional activity of complement proteins in patients with thrombotic APS and healthy controls.
| Parameter | Patients | aPL positive controls | SLE controls | Healthy controls | P |
()
| () | () | () |
| C3, mean ± SD mg/dL (range) | 97.7 ± 26.3 (58–156) | 108.8 ± 39 (61–202) | 77 ± 20 (27–106) | 113.4 ± 40.6 (61–305) | 0.35a, 0.05b, 0.04c | Low C3 (%)1 | 41.2 | 30.8 | 43.8 | 19.2 | 0.74a, 0.76b, 0.04c | C4, mean ± SD mg/dL (range) | 16.9 ± 8.5 (2–41) | 21 ± 7
(12–35)
| 15 ± 6 (5–27) | 23.9 ± 9.6 (12.8–74.4) | 0.19a, 0.58b, 0.001c | Low C4 (%)2 | 63.9 | 38.5 | 56.3 | 17.3 | 0.14a, 0.77b, <0.01c | FB, mean ± SD mg/dL (range) | 33 ± 7.7 (14–46.1) | 31 ± 8 (21.9–47.1) | 28 ± 6 (23–34) | 31.0 ± 8.27 (20–63) | 0.83a, 0.45b, 0.28c | Low FB (%)3 | 3.33 | 0 | 0 | 0 | 0.54a, 0.83b, 0.37c | CH100, mean ± SD Units/mL (range) | 46.9 ± 17.9 (20–70) | 60 ± 27 (23–89) | 63 ± 24 (36–102) | 70.5 ± 31.5 (20–165) | 0.19a, 0.23b, 0.01c | Low CH100 (%)4 | 64.3 | 57.1 | 71.4 | 59.4 | 0.37a, 0.63b, 0.51c |
|
|
APS: antiphospholipid syndrome; aPL positive controls: aPL+ patients without APS clinical criteria; HC: healthy controls; FB: factor B; 1C3 normal range: 83–172 mg/dL; 2C4 normal range: 17–51 mg/dL; 3FB normal range: 19–50 mg/dL; 4CH100 normal range: >70 units/mL. aANOVA comparison of thrombotic APS with aPL+ controls, bANOVA comparison of thrombotic APS with SLE controls, and cANOVA comparison of thrombotic APS with healthy controls.
|